Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.

Endo first got U.S. approval for its extended-release opioid, Opana ER, in 2006. It reformulated that drug in 2012 and claimed the changes made it harder to manipulate physically or chemically to ...

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx ...

Looking at all of its recent acquisitions, you might think Endo Pharmaceutical's (NMS:ENDP) business model echoes another firm's. One like Johnson & Johnson's (NYSE:JNJ - News).

MALVERN, Pa., March 11, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its International Pharmaceuticals ...

Endo Pharmaceuticals (NASDAQ:ENDP) has ended its developments of an octreotide implant to treat a disorder in which the body produces too much growth hormone following a review of its research and ...

Endo Pharmaceuticals, BioDelivery Sciences Present Promising Data On New Chronic Pain Management Product Endo Pharmaceuticals has Everybody Interested as M&A Target Endo Pharmaceuticals ...

Endo Pharmaceuticals Holdings Inc. (ENDP), is a specialty pharmaceutical company. Their particular niche is pain management. The company develops and sells branded and generic pharmaceuticals used ...

The Federal Trade Commission has sued Endo Pharmaceuticals and several other drugmakers, saying they've entered "pay-for-delay" deals that postpone generic versions of its drugs to hit the market.

Endo Pharmaceuticals ( ENDP) is a specialty drug company, with a focus on a few specific areas, namely pain management, urology, and endocrinology. Pain management is the company's forte, led by ...

One of the few things that pharmaceutical companies live for is to release life-changing drugs onto the public market. While pharmaceuticals do not expect to debut blockbuster drugs every year ...

Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its International Pharmaceuticals business, primarily operated through ...